Hadar Ilan 4

What Happened

• Hadar Ilan, Chairman and CEO of Silexion Therapeutics Corp (SLXN), was granted 64,350 restricted share units (RSUs) on Feb 20, 2026 that were fully vested and immediately settled for underlying ordinary shares. The Form 4 reports an acquisition price of $0.00 for the shares (total reported $0), reflecting the RSU settlement rather than an open‑market purchase.

Key Details

• Transaction date: 2026-02-20; Form 4 filed: 2026-02-23 (filed timely based on the report period).
• Transaction code: A (award/grant); reported acquisition price: $0.00.
• Shares acquired/received: 64,350 ordinary shares (per filing).
• Shares owned after transaction: not specified in the provided filing excerpt.
• Relevant footnotes:
  • F2: RSUs were fully vested and immediately settled for underlying ordinary shares; grant approved by the board.
  • F1/F4: Reported share and option counts have been adjusted for prior 1-for-9 and 1-for-15 reverse stock splits.
  • F3: Certain holdings are included for informational purposes only.
• No indication in the filing of a 10b5-1 plan, sale, tax withholding, or late filing.

Context

• This was a compensation award (RSU grant and immediate settlement), not an open-market purchase or sale. Form 4 shows $0.00 as the acquisition price for the award; it does not reflect the market value received or vested compensation taxes withheld (if any). Such awards are common executive compensation and do not, by themselves, indicate a market buy or sell signal.